Academic Journal
Q1EP Europace
About EP Europace
EP Europace is a scholarly journal published by Oxford University Press. SCImago 2025 places it in Q1 with an SJR of 3.446 and an H-index of 145.
Its listed coverage is 1999-2026 and its research categories include Cardiology and Cardiovascular Medicine (Q1); Physiology (medical) (Q1). The 2025 dataset reports 319 documents and 7245 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Cardiac Arrhythmias and Treatments, Atrial Fibrillation Management and Outcomes, Cardiac pacing and defibrillation studies, Cardiac electrophysiology and arrhythmias, Cardiovascular Syncope and Autonomic Disorders, ECG Monitoring and Analysis.
Recent Research Articles
Latest publications matched automatically by ISSN.
Patient-reported outcome measures for atrial fibrillation: a systematic review and evaluation of psychometric properties of symptom severity measures
Jael-Joy Ogendo, Angeliki Darma, Miroslav Mihajlovic, Elena Arbelo et al.
2026-09-08 · DOI: 10.1093/europace/euag252Minimized Atrial Pacing and Atrial Fibrillation Burden in the DANPACE II trial
Maria Hee Jung Park Frausing, Frederik Mikkelsen, Mads Brix Kronborg, Jacob Moesgaard Larsen et al.
2026-09-04 · DOI: 10.1093/europace/euag254Incident heart failure in patients with screening-detected atrial fibrillation: a post hoc analysis of the STROKESTOP and STROKESTOP II studies
Gina Sado, Carl Bonander, Katrin Kemp Gudmundsdottir, Catarina Djupsjö et al.
2026-09-03 · DOI: 10.1093/europace/euag250Selective Activation of Tetrodotoxin-Sensitive Sodium Channels by AaH-II Drives Arrhythmogenic Late Na+ Current in the Heart
Hugo Millet, Maureen Choteau-Bodor, Thomas Stervinou, Floriane Bibault et al.
2026-09-03 · DOI: 10.1093/europace/euag249Incidence and Clinical Implications of Ventricular Tachycardia: A Population-based Approach
Peter Vibe Rasmussen, Anders Holt, Jacob Tønnesen, Charlotte Middelfart et al.
2026-09-03 · DOI: 10.1093/europace/euag234Prognostic Value of Isolated PR Interval Prolongation After Transcatheter Aortic Valve Implantation
Teodor Serban, Marc Salis, Arianna Bettelini, Céline Moser et al.
2026-09-03 · DOI: 10.1093/europace/euag241Combined Unipolar and Bipolar Voltage Mapping at Redo Ablation After Cryoballoon Pulmonary Vein Isolation: Associations With Subsequent Arrhythmia Recurrence
Yazan Mohsen, Syed Yusuf Ali, Shreeram Sabareesan, Kensuke Sakata et al.
2026-09-03 · DOI: 10.1093/europace/euag237Impaired Sinus Rate Behaviour During Ventricular Arrhythmia Is Associated With Adverse Outcomes in ICD Recipients
Maarten Blondeel, Stien Goris, Eva Goethals, Margot Vermeiren et al.
2026-09-03 · DOI: 10.1093/europace/euag251Percutaneous Left Stellate Ganglion Block for Drug-Refractory Supraventricular Arrhythmias in Patients with Advanced Heart Failure and Cardiogenic Shock: A Pilot Study
Filippo Angelini, Arianna Morena, Benedetta De Guidi, Lorenzo Candido Todesco et al.
2026-09-03 · DOI: 10.1093/europace/euag243Pulmonary Vein Isolation Durability in a Randomized Trial comparing Fluoroscopy-only vs. Electroanatomic Mapping Strategies for Pulmonary Vein Isolation With Balloon-in-basket Pulsed-field Ablation
Daniel Rodríguez Muñoz, Isabel López-Alacid, Lucía Cobarro Gálvez, Ez Alddin Rajjoub Al-Mahdi et al.
2026-09-03 · DOI: 10.1093/europace/euag244Edoxaban Antithrombotic Therapy in Diabetic Patients with Atrial Fibrillation and Stable Coronary Artery Disease: The EPIC-CAD Trial
Seunghan Lee, Min Soo Cho, Do-Yoon Kang, Jung-Min Ahn et al.
2026-09-03 · DOI: 10.1093/europace/euag247Bleeding-Related Conditions, Procedural Safety, and Mortality After Left Atrial Appendage Closure
Grégoire Massoullié, Come Fleury, Emeline Tourret, Simon Berger et al.
2026-09-03 · DOI: 10.1093/europace/euag235Pulsed-Field Ablation for Atrial Fibrillation with an Extended Protocol: the Extended PFA Dose Study
Corinne Isenegger, Alexander Breitenstein, Niklas Stauffer, Pascal Koepfli et al.
2026-09-03 · DOI: 10.1093/europace/euag253Essential antiarrhythmic drug accessibility worldwide: A multi-survey study and comprehensive evaluation of access and supply challenges
Pieter G Postema, Niels D Reijnhout, Federico Ballacci, Evert A Manders et al.
2026-09-02 · DOI: 10.1093/europace/euag220Identifying patients at low risk for atrial fibrillation after cryptogenic stroke: the PAVA score
Baptiste Maille, Noémie Resseguier, Eloi Marijon, Nathalie Behar et al.
2026-09-02 · DOI: 10.1093/europace/euag183Sex-associated differences in lesion delivery and atrial fibrillation recurrence after cryoballoon ablation
Emanuel Heil, Matthias Bock, Julia Knocks, Jan Paul Rudolph et al.
2026-09-02 · DOI: 10.1093/europace/euag189Programmed ventricular stimulation for risk stratification in symptomatic athletes with nonischemic left ventricular scar and preserved ejection fraction
Luigi Sciarra, Fabrizio Ricci, Elena Cavarretta, Zefferino Palamà et al.
2026-09-02 · DOI: 10.1093/europace/euag160Cryoballoon ablation versus antiarrhythmic drug therapy as initial treatment for persistent atrial fibrillation: the multicenter randomized CEPAF trial
Tianyou Ling, Yazhou Lin, Yangyang Bao, Lin Chen et al.
2026-09-01 · DOI: 10.1093/europace/euag230Development and Validation of the GLORIA-AF Stroke Weighted Risk Score for Patients with Atrial Fibrillation
Yifan Xie, Wenhui Li, Yanda Meng, Tianjin Huang et al.
2026-08-29 · DOI: 10.1093/europace/euag236Safety and Effectiveness of a Novel Dual-Energy Radiofrequency/Pulsed Field Ablation Catheter: 12 Month Results of the FlexPulse Study
Ayman A Hussein, Gediminas Rackauskas, Sri Sundaram, Jonathan P Piccini et al.
2026-08-29 · DOI: 10.1093/europace/euag238Reviews
Community Reviews
Version History
September 8, 2026 at 12:07 am
September 8, 2026